Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

Morteza Shakhsi Niaee; Fatemeh Cheraghi; Peyman Namdar; Abbas Allami; Amin Karampour; Leila Zolghadr; Amir Javadi; Mehran Varnaseri; Masoumeh Karamyan; Mohammad Yadyad; Ramin Jamshidian; Behzad Bijani; Yazdan Naderi; Nematollah Gheibi; Fatemeh Amini

Return

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

Author: Morteza SHAKHSI NIAEE ¹ ; Fatemeh CHERAGHI ¹ ; Peyman NAMDAR ² ; Abbas ALLAMI ³ ; Amin KARAMPOUR ³ ; Leila ZOLGHADR ⁴ ; Amir JAVADI ⁵ ; Mehran VARNASERI ⁶ ; Masoumeh KARAMYAN ⁶ ; Mohammad YADYAD ⁶ ; Ramin JAMSHIDIAN ⁶ ; Behzad BIJANI ⁷ ; Yazdan NADERI ⁸ ; Nematollah GHEIBI ⁸ ; Fatemeh AMINI ⁹
Author Information

1. Sciences and Technology Park
2. Department of Surgery, Qazvin University of Medical Sciences
3. Department of Infectious Diseases, Clinical Research Development Unit, BouAliSina Hospital, Qazvin University of Medical Sciences
4. Department of Chemistry, Imam Khomeini International University
5. Department of Social Sciences School of Medicine, Qazvin University of Medical Sciences
6. Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences
7. Department of Infectious Diseases, Qazvin University of Medical Sciences
8. Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences
9. Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences
Publication Type:Journal Article
Keywords: Dose-respond relationship; Ivermectin; Randomized controlled trial; SARS-COV-2
From: Asian Pacific Journal of Tropical Medicine 2021;14(6):266-273
CountryChina
Language:Chinese
Abstract: Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin (200 μg/kg), three low interval doses of ivermectin (200, 200, 200 μg/kg), single dose ivermectin (400 μg/kg), and three high interval doses of ivermectin (400, 200, 200 μg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O